FRANKLIN LAKES, N.J., Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) and Surgery business units are the first in the medical technology industry to achieve a diamond-level rating for all seven supply chain resilience domains of the Healthcare Industry Resilience Collaborative's (HIRC) Resiliency Badging program.
"Achieving HIRC's Diamond Status Resiliency Badge recognizes BD's commitment to building a resilient end-to-end supply chain across multiple product categories and our relentless pursuit of process excellence and continuous improvement," said Tony Ezell, executive vice president and president of the Americas region for BD. "Hundreds of millions of patients depend on BD, and this recognition is a testament to the work our team does every day to ensure products arrive on time and in the right quantities."
HIRC is a non-profit health care supply chain trade association founded in 2019 by a group of health care systems and trading partners focused on increasing transparency and resiliency. The Resiliency Badge Program includes a rigorous audit to assess supply chain resiliency, ensuring alignment with HIRC's standards for supply continuity, risk mitigation and operational efficiency. After completing a comprehensive audit, HIRC recognized BD for differentiated resiliency in all domain areas for its Surgery and UCC businesses, including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management and continency planning, and operational health.
BD was one of the first companies recognized by HIRC after receiving the Transparency Partner Badge in 2023. This diamond-level distinction builds on that recognition and demonstrates BD's ongoing investment in its supply chain and manufacturing operations, including increasing safety stock and capacity to allow greater flexibility for the most critical products and improving order management interfaces so customers have real-time insights into supply and deliveries.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | Investors: |
Fallon McLoughlin | Adam Reiffe |
BD Corporate Communications | BD Investor Relations |
201.258.0361 | 201.847.6927 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$193.93 |
Daily Change: | 1.40 0.73 |
Daily Volume: | 1,075,655 |
Market Cap: | US$55.590B |
October 08, 2025 September 22, 2025 August 04, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load